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Abstract
Methicillin-resistant Staphylococcus aureus (MRSA) is an important cause of both healthcare-associated MRSA (HA-MRSA) and
community-associated MRSA (CA-MRSA) infections. Severe MRSA infections have been associated with the virulence factor Panton–
Valentine leukocidin (PVL). The aim of this study was to investigate susceptibility patterns, the presence of toxin genes, including that encoding
PVL, and clonality among MRSA isolates collected from patients in Greece over a 12-year period. MRSA isolates were collected from January
2001 to December 2012 from six different hospitals. Antibiotic susceptibility was determined with the disk diffusionmethod and the Etest. The
presence of the toxic shock syndrome toxin-1 gene (tst), the enterotoxin gene cluster (egc) and the PVL gene was tested with PCR. The
genotypic characteristics of the strains were analysed by SCCmec and agr typing, and clonality was determined with pulsed-ﬁeld gel
electrophoresis and multilocus sequence typing. An increasing rate of MRSA among S. aureus infections was detected up to 2008. The majority
of PVL-positive MRSA isolates belonged to a single clone, sequence type (ST)80-IV, which was disseminated both in the community and in
hospitals, especially during thewarmestmonths of the year. Carriage of tstwas associatedwith ST30-IV, whereas egcwas distributed in different
clones. CA-MRSA isolateswere recoveredmainly from skin and soft tissue infections, whereasHA-MRSA isolateswere associatedwith surgical
and wound infections. During the period 2001–2012, ST80-IV predominated in the community and inﬁltrated the hospital settings in Greece,
successfully replacing other PVL-positive clones. The predominance of ST239-III in HA-MRSA infections was constant, whereas new clones
have also emerged. Polyclonality was statistically signiﬁcantly higher among CA-MRSA isolates and isolates from adult patients.
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Introduction
Staphylococcus aureus is the main cause of purulent infections
[1]. The classiﬁcation of S. aureus as one of the most important
human pathogens is largely based on its virulence potential and
ubiquitous occurrence as a colonizer in humans, domestic
animals, and livestock [2].
In the modern era, it is estimated that 25–35% of healthy
human individuals carry S. aureus on the skin or mucous
membranes [2]. This means that up to 2 billion individuals
carry S. aureus worldwide, and conservative estimates based
on Dutch and US prevalence data predict that c. 2–53 million
people carry methicillin-resistant S. aureus (MRSA) [3]. MRSA
is one of the most signiﬁcant healthcare-associated pathogens,
causing a wide range of infections. The ﬁrst MRSA isolate was
reported in 1960, and since then various clones have dissem-
inated worldwide [2]. The prevalence of MRSA bacteraemia
ª2014 The Authors
Clinical Microbiology and Infection ª2014 European Society of Clinical Microbiology and Infectious Diseases
ORIGINAL ARTICLE BACTERIOLOGY
varies from 1% in Norway to 67% in Japan [2,4]. Factors
contributing to the occurrence of MRSA infections are
cross-transmission via the hands of healthcare workers and
high selective pressure exerted by broad-spectrum antibiotic
therapy [5]. As a result of clonal spread, outbreaks of MRSA
have been described in hospital settings worldwide, and MRSA
has become endemic in many international healthcare settings
(healthcare-associated MRSA (HA-MRSA)) [5]. Besides health-
care-associated infections, MRSA causes community-associ-
ated infections (community-associated MRSA (CA-MRSA))
among patients without predisposing risk factors, especially
skin and soft tissue infections (SSTIs) and necrotizing pneu-
monia [2,3]. Genotyping of MRSA is important, in order to
detect outbreaks, assess the dissemination of virulent strains,
and understand its epidemiology. This is achieved by identifying
the presence of important mobile genetic elements, which
include the methicillin resistance gene mecA on the various
SCCmec elements, the bacteriophage-encoded Panton–Valen-
tine leukocidin (PVL) toxin, and many resistance determinants
conveyed by plasmids or transposons [6–8]. PVL-positive
MRSA isolates are strongly associated with SSTIs and severe
community-onset pneumonia [9,10]. The ﬁrst PVL-positive
MRSA isolate in Greece was identiﬁed at the University
General Hospital of Patras from an intravenous catheter
culture of a premature baby in 1998, suggesting that it was
acquired from a healthcare worker [11]. During the year 2000,
another ten PVL-positive MRSA isolates were obtained from
patients with underlying diseases, and it was obvious that there
had been an increase in the incidence of CA-MRSA and
HA-MRSA infections caused by PVL-positive strains [11]. A
parallel increase was also observed in the overall percentage of
total MRSA infections during the period of the above studies,
probably caused by the spread of PVL-positive strains. It has
been reported that CA-MRSA has a faster growth rate than
HA-MRSA, resulting in successful colonization [12]. In another
Greek study performed from 2001 to 2003, a signiﬁcant
increase in the number of PVL-positive S. aureus isolates, most
of which were MRSA, was found [13]. Among CA-MRSA
isolates, 72% carried the PVL genes, and 23% of HA-MRSA
isolates were also PVL-positive [13]. The prevalence of
CA-MRSA infections varies widely from one country to
another [14]. For example, many differences exist between
the epidemiology of CA-MRSA in the USA and that in Europe
[2]. In the USA, CA-MRSA is one of the most common causes
of SSTIs in patients from emergency departments, and one
clone, USA300 (sequence type (ST)8-SCCmec IV), predomi-
nates [2]. In Europe, the prevalence of CA-MRSA is much
lower, but it is increasing, especially in countries where the
incidence of HA-MRSA is low, such as Denmark and The
Netherlands [15]. Many different CA-MRSA clones have been
identiﬁed, of which the ST80-SCCmec IV European clone is the
most widely disseminated [15]. Recently, however, several
European countries have been confronted with a rise in the
prevalence of USA300 strains [14].
The aim of the present study was to estimate the
prevalence and clonal distribution of PVL-positive MRSA
among healthcare-associated and community patients with
staphylococcal infections in a wide geographical area of Greece
during a 12-year period.
Materials and Methods
Bacterial isolates and hospitals
Four thousand six hundred and fourteen MRSA isolates from
six S. aureus collections were studied. These collections
originated from six different Greek hospitals serving three-
ﬁfths of the total Greek population: University General
Hospital of Patras (2259 isolates) and Karamandaneion Chil-
dren’s Hospital of Patras (291 isolates), both located in
south-western Greece; ‘P. & A. Kyriakou’ Children’s Hospital
(139 isolates) and General Children’s Hospital Pentelis (46
isolates), both located in Athens; University Hospital of
Ioannina (80 isolates), located in north-western Greece; and
University Hospital of Larissa (1799 isolates), located in central
Greece. All isolates were recovered from different inpatients
and outpatients with S. aureus infection (one isolate per
patient) during a 12-year period from January 2001 to
December 2012. Each isolate was sent to the National
Reference Laboratory for Staphylococci, with a report
describing demographics and clinical data: age and sex of the
patients, clinical specimen and date of sampling, underlying
disease, hospital ward, and whether the isolate was epidemi-
ologically representative of a cluster. Children’s hospitals
admit patients up to the age of 14 years.
Isolates obtained within 48 h of hospital admission were
deﬁned as CA-MRSA, as were isolates from patients with
infection diagnosed in an outpatient department, provided that
there was no history in the past year of hospitalization,
admission to a nursing home, skilled nursing facility, or hospice,
or association with dialysis, surgery, permanent indwelling
catheters, or medical devices. Isolates obtained >48 h follow-
ing admission were deﬁned as HA-MRSA [16].
S. aureus identiﬁcation
Isolates were identiﬁed on the basis of colony morphology,
Gram stain, catalase production, and the coagulase test (Slidex
StaphPlus; bioMerieux,Marcy l’Etoile, France), and identiﬁcation
was veriﬁed with molecular methods (PCR for 16S rRNA and
nuc genes) [17].
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Antimicrobial susceptibility testing
Susceptibility testing was performed with the disk diffusion
method, according to CLSI guidelines for cefoxitin, tobramy-
cin, gentamicin, rifampicin, kanamycin, erythromycin, clinda-
mycin, ciproﬂoxacin, and sulphamethoxazole–trimethoprim,
and according to the EUCAST breakpoints for fusidic acid
(BBL disks; Becton Dickinson, Le Pont de Claix, France)
[18,19]. Oxacillin, vancomycin, teicoplanin, daptomycin and
linezolid MICs were determined with a gradient method (Etest;
bioMerieux) [18]. Final determination of vancomycin MICs was
achieved after testing, with the agar dilution method (antibiotic
concentrations: 0.5, 1, 1.5, 2, 2.5, 3, 3.5 and 4 mg/L), those
isolates showing MIC levels of >2 mg/L in the Etest [18]. All
isolates with a cefoxitin zone diameter of ≤21 mm were tested
with a latex agglutination test (Slidex MRSA Detection;
bioMerieux) for the presence of penicillin-binding protein 2a,
and with PCR for mecA [17]. Multiresistant isolates were those
showing resistance to three or more classes of antimicrobial.
Toxin gene detection
Genes encoding PVL (lukS/lukF-PV) and toxic shock syndrome
toxin-1 (tst), and the egc operon of the enterotoxin gene cluster
(sem and seg), were investigated with PCR [20]. PCR products
were analysed by electrophoresis on agarose 1% w/v gels.
S. aureus strains ATCC49775 (PVL-positive, agr3), Fri 913
(tst-positive, agr1), Fri 137 (egc operon-positive, agr2) and
HT 20000195(agr4)wereusedaspositivecontrolsforPCRs[20].
Molecular typing
DNA extraction and pulsed-ﬁeld gel electrophoresis (PFGE) of
SmaI DNA digests were performed in a CHEF DR III appara-
tus (Bio-Rad Laboratories, Richmond, CA, USA), as described
elsewhere [21]. Visual interpretation of the PFGE banding
patterns and the assignments of types (pulsotypes) were
performed for all MRSA isolates, according to the criteria of
Tenover et al. [21]. PFGE types were named with capital
letters. agr groups and SCCmec types were deﬁned by PCR
[20,22]. Multilocus sequence typing was performed on 946
selected representative isolates from all MRSA collections
according to agr, PFGE type, SCCmec type, toxin gene proﬁle
and antibiotic resistance pattern (www.mlst.net). Clones were
deﬁned according to ST-SCCmec type.
Statistical analysis
Statistical analysis was performed with SPSS version 19.0
(SPSS, Chicago, IL, USA). The prevalence estimates for MRSA
by hospital, sex, age, year, type, origin (healthcare-associated
or community-associated), clone, toxin gene carriage and
MIC90 value were compared by the use of Pearson’s chi-square
test or Fisher’s exact test. Results were considered to be
statistically signiﬁcant at p <0.05, and values are expressed as
percentages.
Results
All isolates with a cefoxitin zone diameter of ≤21 mm were
penicillin-binding protein 2a-positive, carried mecA, and were
characterized as MRSA. The percentage of MRSA isolates in
S. aureus infections in all six hospitals showed a gradual increase
from 2001 to 2008, and slightly lower rates up to 2012 (Fig. 1).
The majority of MRSA isolates were recovered from adults
(3378, 73.2%) and male patients (2811, 60.9%). In total, 3345
isolates were CA-MRSA, and the remaining 1269 were
HA-MRSA, as deﬁned according to epidemiological criteria.
An increasing incidence of CA-MRSA in total during the study
period was observed, reaching 68.6% of MRSA isolates (from
44.9% to 68.6%), showing a statistically signiﬁcant difference
from HA-MRSA in 2012 (p <0.001). There was a greater
proportion of multiresistant MRSA isolates in adults (533/
3378, 15.8%) than in children (63/1236, 5.1%). HA-MRSA
isolates showed signiﬁcantly higher rates of resistance to the
majority of the antimicrobials tested with the disk diffusion
method than CA-MRSA isolates (Fig. 2). Moreover, CA-MRSA
isolates showed high rates of resistance to kanamycin (89.5%),
fusidic acid (88.4%), erythromycin (19.8%), and tobramycin
(21.0%). Three hundred and ninety-seven isolates (11.9%)
were resistant to macrolides and lincosamides (318 isolates
showing inducible resistance, and the remaining 79 showing
constitutive resistance) (Fig. 2).
Four hundred and sixty-nine mecA-positive isolates (10.2%)
showed oxacillin MICs of <4 mg/L. The MIC90 of vancomycin
was 2 mg/L (0.25–2 mg/L), that of linezolid was 1.5 mg/L
(0.094–2 mg/L), and that of daptomycin was 0.5 mg/L (0.016–
1 mg/L). No statistically signiﬁcant difference was observed in
MIC90 values between CA-MRSA and HA-MRSA, or among
the six participating hospitals.
Among the 3345 CA-MRSA isolates, 2736 (81.8%) were
recovered from SSTIs, 399 (11.9%) from abscesses, and the
remainder from bacteraemias (79, 2.4%), wound infections (52,
1.6%), respiratory tract infections (47, 1.4%), and urinary tract
infections (32, 0.9%).
Among the 1269 HA-MRSA isolates, 462 (36.4%) were
recovered from bacteraemias, 447 (35.2%) from SSTIs, 168
(13.2%) from abscesses, and the remainder from surgical
wound infections (92, 7.2%), especially when prosthetic
devices were present, respiratory tract infections (87, 6.9%),
and urinary tract infections (13, 1.1%).
The frequency of ST80-IV increased from 28.6% in 2001 to
73.3% in 2012 (Table 1). Isolates belonging to this clone were
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characterized as SCCmec IV; the majority were C/agr3,
whereas ten were classiﬁed as A/agr3, B/agr3, H/agr3, and
L/agr3. In 2004, we detected, for the ﬁrst time, one ST80-IV
isolate, classiﬁed as C/agr1. Since then, 14 more isolates have
been identiﬁed with that proﬁle. In 2007, 2008, and 2011, four
strains were classiﬁed as ST80-IV and C/agr2.
ST80-IV was signiﬁcantly more frequent in the summer
season (June to September) than in winter (October to
January) (1447 vs. 610 isolates, p <0.001), whereas the
remaining clones were distributed equally throughout the
year. Eight hundred and sixty-eight ST80-IV isolates were
recovered from 1236 children examined, and 1970 from 3378
adults (70.2% vs. 58.3%, p <0.001).
The other main clones characterized in this study were:
ST239-III (1051 isolates), ST30-IV (453 isolates), ST377-V (60
isolates), and ST225-II (52 isolates). ST239 isolates carrying
SCCmec III belonged to two main PFGE types (E and B),
whereas 12 isolates were classiﬁed as C, G, K, L, and N,
combined with agr1,2,3. ST30-IV isolates were classiﬁed as A
and O, combined with agr1,3, whereas ST377 isolates carried
SCCmec V and were G/agr1,3. This clone was detected for the
ﬁrst time in 2004, and reached its highest prevalence in 2008,
with 26 isolates in total. ST225 isolates carrying SCCmec II
were classiﬁed as H (38 isolates), A, B, C, D, E, and G,
combined with agr1,2,3. Minor clones in this collection were:
ST8-IVc (H/agr1), ST72-IV (E/agr1 and B/agr1), ST121-V (R/
agr3,4), ST461-NT (A/agr3), ST770-NT (E/agr1), ST22-IV (G/
agr1,2,3 and T/agr1,2,3), ST97-V (A/agr1,2 and E/agr1,2),
ST1659-II (B/agr1), ST5-IV (B/agr1,2 and C/agr1,2), ST7-IV
(C/agr1), ST45-IV (H/agr1), ST217-IV (F/agr1), ST935-V (H/
agr2), ST1-IV (B/agr1,3, C/agr1,3, and H/agr1,3), ST585-III (C/
agr1), ST714-IV (A/agr3), ST842-NT (C/agr1), ST2486-IV
(C/agr3), and ST2487-IV (C/agr1) (Fig. 3).
Polyclonality was observed to a lesser extent among
children than among adults (13 vs. 21 clones, p 0.172).
From 2001 to 2012, ST80-IV was found in ﬁve hospital units,
which included both adult and paediatric services. The adult
services included the outpatient department, the trauma unit,
the intensive-care unit, the internal medicine unit, the surgery
unit, the nephrology unit, and the cardiopulmonary unit. The
paediatric services included the outpatient department, the
newborn and paediatric intensive-care unit, and the surgery and
orthopaedic wards. ST80-IV was signiﬁcantly more frequent in
adults and paediatric outpatients than in patients of other wards
(59.6% vs. 40.4%, p <0.001).
Genes encoding PVLwere detected in 2946 isolates: 2825 for
ST80-IV, 54 for ST377-V, and one to eight each for ST8-IVc,
FIG. 1. Annual percentage of methicillin-resistant Staphylococcus aureus (MRSA) among S. aureus infections in all participating hospitals. AKCH, ‘P. &
A. Kyriakou’ Kyriakou Children’s Hospital; GCHP, General Children’s Hospital Pentelis; KHP, Karamandaneion Children’s Hospital of Patras; UGHP,
University General Hospital of Patras; UHI, University Hospital of Ioannina; UHL, University Hospital of Larissa.
FIG. 2. Antibiotic resistance patterns among community-associated
methicillin-resistant Staphylococcus aureus (CA-MRSA) and health-
care-associated methicillin-resistant S. aureus (HA-MRSA), as deter-
mined with the disk diffusion method. KAN, kanamycin; FUS, fusidic
acid; E, erythromycin; CC, clindamycin; TOB, tobramycin; RA,
rifampicin; GM, gentamicin; CIP, ciproﬂoxacin; SXT, sulphamethoxaz-
ole–trimethoprim.
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ST30-IV, ST72-IV, ST121-V, ST225-II, ST239-III, ST461-NT,
ST714-IV, and ST770-NT (Table 2). One hundred and eleven
isolates (2.4%) carried tst. The majority of these isolates were
ST30-IV (76 isolates) and ST239-III (18 isolates), and the
remaining 17 were ST225-II, ST22-IV, ST97-V, and ST1659-II.
No isolate simultaneously carried both a PVL gene and tst.
Isolates carrying the egc operon were classiﬁed into 16 clones:
ST80-IV (222 isolates), ST30-IV (102 isolates), ST239-III (52
isolates), and ST5-IV, ST7-IV, ST22-IV, ST45-IV, ST72-IV,
ST97-V, ST121-V, ST217-IV, ST225-II, ST377-V, ST714-IV,
ST935-V, and ST2486-IV (1–13 isolates each) (Table 2). Among
the 495 egc-positive isolates, 89 simultaneously carried tst, the
majority being ST30-IV (71 isolates), and 248 simultaneously
carried PVL genes, the majority of them being ST80-IV (210
isolates). Two of 13 PVL-negative ST80-IV isolates carried the
egc operon.
PFGE and multilocus sequence typing analysis of the
PVL-positive MRSA isolates in the present study revealed the
TABLE 1. Frequencies of methicil-
lin-resistant Staphylococcus aureus
(MRSA) by clone during the 12-year
study period (2001–2012); the per-
centage of clones was calculated
within each year
MRSA
total
ST80-IV
N (%)
ST239-III
N (%)
ST30-IV
N (%)
ST377-V
N (%)
Other STs
N (%)
2001 84 24 (28.6) 41 (48.8) 18 (21.4) – 1 (1.2)
2002 155 54 (34.8) 79 (51.0) 19 (12.3) – 3 (1.9)
2003 167 75 (45.0) 64 (38.3) 27 (16.2) – 1 (0.5)
2004 315 157 (49.8) 117 (37.2) 36 (11.4) 4 (1.3) 1 (0.3)
2005 377 197 (52.3) 131 (34.7) 43 (11.4) 4 (1.1) 2 (0.5)
2006 496 280 (56.5) 144 (29.0) 58 (11.7) 5 (1.0) 9 (1.8)
2007 610 404 (66.2) 113 (18.5) 65 (10.7) 5 (0.8) 23 (3.8)
2008 847 589 (69.5) 120 (14.2) 67 (7.9) 26 (3.1) 45 (5.3)
2009 553 378 (68.4) 89 (16.1) 45 (8.1) 7 (1.3) 34 (6.1)
2010 561 368 (65.6) 72 (12.8) 39 (7.0) 7 (1.2) 75 (13.4)
2011 198 128 (64.6) 38 (19.2) 16 (8.1) – 16 (8.1)
2012 251 184 (73.3) 43 (17.1) 20 (8.0) 2 (0.8) 2 (0.8)
Total 4614 2838 (61.6) 1051 (22.5) 453 (9.8) 60 (1.4) 212 (4.7)
ST, sequence type.
FIG. 3. Clonal distribution of methicillin-resistant Staphylococcus aureus isolates recovered from patients admitted to the participating tertiary-care
hospitals in Greece, from 2001 to 2012.
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spread of a main clone among MRSA isolates in the community
and in the geographically distinct participating hospitals. In
total, 2825 (99.5%) of 2838 ST80-IV isolates were positive for
PVL genes by PCR. Only 13 ST80-IV isolates were PVL-neg-
ative, and the ﬁrst of them was detected in 2004. None of the
ST80-IV isolates carried tst.
The main healthcare-associated clone in our collection was
ST239-III. This clone showed a gradual decrease (Table 1).
ST80-IV, ST30-IV and ST377-V were also found among
HA-MRSA isolates. The presence of ST225-II was also signiﬁcant
in this group (44 isolates), and it was characterized by a low
percentage of PVL gene carriage (4/44, 9.1%) and higher
frequenciesof tstandegc (10/44and8/44, respectively) (Table 2).
Discussion
The present study revealed a predominance of ST80-IV (61.6%
in total and 88.8% in CA-MRSA) in the community, and of
ST239-III in hospitals (22.5% in total and 60.8% in HA-MRSA).
Furthermore, the MRSA clonal diversity that has been
observed during recent years, mainly among adults, may
reﬂect frequent travel and the importation of new MRSA
clones into Greece, as these are present in other countries as
well. Speciﬁcally, even though ST8-IV (USA300) is the most
successful in the USA, in Greece it was identiﬁed for the ﬁrst
time in 2008, and it is still being identiﬁed in sporadic cases
without being spread [2].
The multidrug-resistant phenotype is a particular charac-
teristic of MRSA, related to the global presence and spread of
multidrug-resistant clones [23]. The homogeneous lack of
susceptibility to all b-lactams, which is characteristic of
methicillin-resistant strains, together with the continuous
accumulation and organization of many resistance genes have
made infections with this species particularly difﬁcult to treat
[24]. This extensive antibiotic resistance is seen for many
classes of antimicrobial, such as aminoglycosides, macrolides,
lincosamides, and ﬂuoroquinolones, which, as demonstrated in
this study, appeared to maintain a low level of activity against
HA-MRSA. Moreover, no resistance to vancomycin, dapto-
mycin or linezolid was observed during this period. Never-
theless, a slight but continuous increase in the level of
non-susceptibility to vancomycin has been found by many
studies all around the world [23]. Seasonal variation in
S. aureus infections is controversial. The present study con-
ﬁrmed that the majority of infections caused by ST80-IV
(1447/2838) occurred during the warmest months of the year,
probably because of the increased time that people spend
outdoors and closer contact with the environment, especially
among children, predisposing to skin damage and infection
[24]. In a more recent study, Mermel et al. [25] found
evidence for a seasonal effect on the frequency of CA-MRSA
isolates per emergency department visit in both paediatric and
adult patients. They found a two-fold to three-fold increased
incidence of MRSA infections in paediatric patients during the
second two quarters of the last decade. A lower degree of
seasonal variation was observed for adult CA-MRSA infections
[25].
None of the PVL-positive isolates in the present study
carried tst. In contrast, Rossney et al. [26] found six of 25 ST30
isolates that harboured tst along with PVL genes, and ﬁve of
them were CA-MRSA strains. In our collection, the ST30-IV
isolates had a very low percentage of PVL gene carriage (1.8%)
and a relatively high percentage of tst carriage (16.8%).
The predominant CA-MRSA clones differ between conti-
nents. USA300 (ST8) predominates in the USA, the European
clone (ST80) predominates in Europe, and the Southwest Paciﬁc
clone (ST30) predominates inAustralia, Asia, and SouthAmerica
[27], but, owing to increased travel, these strains are spreading
throughout theworld. It is very interesting, however, that, in the
northern countries of Europe, such as Denmark, both the
USA300 clone and the European clone are present [14]. Spain
and Portugal have high rates of HA-MRSA but low, albeit
increasing, rates of CA-MRSA. In two Spanish studies, ST8-IV
TABLE 2. Prevalence rates of methicillin-resistant Staphylo-
coccus aureus (MRSA) and comparison between commu-
nity-asociated and hospital-associated infections, identiﬁed
according to epidemiological criteria (community-associated
MRSA (CA-MRSA) and healthcare-associated MRSA
(HA-MRSA)), clone, and toxin gene carriage (lukS/lukF-PV,
tst, and egc operon)
Total N
CA-MRSA
N (%)
HA-MRSA
N (%) p
ST80-IV 2838 2520 (88.8) 318 (11.2) <0.001
ST30-IV 453 319 (70.4) 134 (29.6) <0.001
ST377-V 60 46 (76.7) 14 (23.3) <0.001
ST239-III 1051 346 (32.9) 705 (60.8) <0.001
ST225-II 52 8 (15.4) 44 (84.6) <0.001
Other clones 160 106 (66.3) 54 (33.7) <0.001
PVL in total 2946 2602 (88.3) 344 (11.7) <0.001
PVL in ST80-IV 2825 2515 (96.7) 310 (90.1) <0.001
PVL in ST30-IV 8 6 (0.2) 2 (0.6) <0.001
PVL in ST377-V 54 42 (1.6) 12 (3.5) 0.453
PVL in ST239-III 7 5 (0.2) 2 (0.6) <0.001
PVL in ST225-II 4 – 4 (1.2) –
PVL in other clones 48 34 (1.3) 14 (4.0) 0.606
tst in total 111 43 (38.74) 68 (61.26) 0.034
tst in ST30-IV 76 35 (81.40) 41 (60.29) 0.080
tst in ST239-III 18 6 (13.95) 12 (17.65) 0.635
tst in ST225-II 10 – 10 (14.71) –
tst in other clones 7 2 (4.65) 5 (7.35) 0.119
egc in total 495 322 (65.1) 173 (34.9) <0.001
egc in ST80-IV 222 148 (46.0) 74 (42.8) 0.758
egc in ST30-IV 102 64 (19.9) 38 (22.0) 1
egc in ST239-III 52 41 (12.7) 8 (4.5) 0.960
egc in ST225-II 13 5 (1.5) 8 (4.5) 0.196
egc in other clones 106 64 (19.9) 42 (24.3) 0.767
PVL, Panton–Valentine leukocidin; ST, sequence type.
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(USA300) was the most frequent clone, and these PVL-positive
isolates were associated with immigrants from South America,
mainly Ecuador and Bolivia [14]. Portugal has a very high rate of
HA-MRSA in hospitals, but a very low rate of CA-MRSA [14]. A
recent report from the German Reference Laboratory for
Staphylococci suggests an increase in prevalence of the Euro-
pean clone, and also the emergence of a USA300-like ST8-IV
PVL-positive clone, most likely imported from the USA [14].
In the present study, we identiﬁed the presence of the
European clone ST80-IV in both CA-MRSA (88.8%) and
HA-MRSA (11.2%). The vast majority, 99.5% (2825/2838), of
the above isolates carried lukS/lukF-PV genes encoding PVL. In
another Greek study conducted at one hospital in Athens
during 2009, 30.7% of S. aureus isolates recovered from
outpatients were characterized as MRSA; all were PVL-positive
and classiﬁed as ST80-IV [28]. Moreover, in 2008, Dailiana
et al. [29] showed that, in a 4-year S. aureus collection in
central Greece, the majority of PVL-positive MRSA isolates
(54/58) were ST80 and the remainder were ST377. We can
conclude that ST80-IV is dominant in Greece, especially
concerning CA-MRSA infections, and it has also been reported
that this particular clone is expanding in other European
countries, such as France, The Netherlands, and Switzerland
[14]. The most common healthcare-associated clone in
Greece remains ST239-III, followed by ST80-IV, which is
successfully spreading in hospitals. Hospital invasion has also
been reported for clones in other countries [2]. We assume
that this hospital invasion is a result of the extensive use of
b-lactam antibiotics in combination with a very low rate of
routine MRSA colonization screening in the staff [14]. More-
over, Vandenesch et al. [30] reported that isolates carriying
PVL genes and SCCmec IV may have a selective advantage
among community-based MRSA pathogens. Okuma et al. [12]
have suggested that CA-MRSA should show enhanced ecolog-
ical ﬁtness, as it has a shorter doubling time than HA-MRSA.
The epidemiological characteristics of MRSA in the countries
neighbouring Greece vary. Despite the large size of Turkey, a
single predominant clone, ST239-III, circulates in hospitals in
different regions, and only few new types of MRSA have been
introduced over ten years (1997–2006) [31]. In contrast, studies
have shown that, in Italy, the main HA-MRSA clone is ST228-I,
and that ST239-III has been present for only a short time [8].
In conclusion, this study has shown the predominance of a
single MRSA clone in Greece, ST80-IV, which is prevalent in
other European countries as well. Moreover, it appears not
only to cause community-associated infections, but also to be
an emerging cause of healthcare-associated infections. Special
attention is required in diagnosing and identifying MRSA, in
order to enable the prescription of appropriate antibiotic
therapeutic regimens to adequately control the possible severe
complications, and to prevent the dissemination of this
pathogen.
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